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Objective: Exaggerated central nervous system (CNS) inﬂammatory responses to peripheral stressors may be
implicated in delirium. This study hypothesised that the IL-1β family is involved in delirium, predicting increased
levels of interleukin-1β (IL-1β) and decreased IL-1 receptor antagonist (IL-1ra) in the cerebrospinalﬂuid (CSF) of
elderly patients with acute hip fracture. We also hypothesised that Glial Fibrillary Acidic Protein (GFAP) and
interferon-γ (IFN-γ) would be increased, and insulin-like growth factor 1 (IGF-1) would be decreased.
Methods: Participants with acute hip fracture aged N60 (N= 43)were assessed for delirium before and 3–4 days
after surgery. CSF samples were taken at induction of spinal anaesthesia. Enzyme-linked immunosorbent assays
(ELISA) were used for protein concentrations.
Results: Prevalent delirium was diagnosed in eight patients and incident delirium in 17 patients. CSF IL-1β
was higher in patients with incident delirium compared to never delirium (incident delirium 1.74 pg/ml
(1.02–1.74) vs. prevalent 0.84 pg/ml (0.49–1.57) vs. never 0.66 pg/ml (0–1.02), Kruskal–Wallis p = 0.03).
CSF:serum IL-1β ratios were higher in delirious than non-delirious patients. CSF IL-1ra was higher in prevalent
delirium compared to incident delirium (prevalent delirium 70.75 pg/ml (65.63–73.01) vs. incident 31.06 pg/ml
(28.12–35.15) vs. never 33.98 pg/ml (28.71–43.28), Kruskal–Wallis p = 0.04). GFAP was not increased in
delirium. IFN-γ and IGF-1 were below the detection limit in CSF.
Conclusion: This study provides novel evidence of CNS inﬂammation involving the IL-1β family in delirium and
suggests a rise in CSF IL-1β early in delirium pathogenesis. Future larger CSF studies should examine the role of
CNS inﬂammation in delirium and its sequelae.© 2014 Elsevier Inc. All rights reserved.Introduction
Delirium is a serious, common neuropsychiatric condition with
major implications for morbidity and mortality in frail older people
[1]. It is triggered by peripheral insults such as infection, trauma orrch Group, Geriatric Medicine
ﬁrmary of Edinburgh, 51 Little
: +44 131 242 6481; fax: +44
roanna.hall@ed.ac.uk (R.J. Hall).surgery, the pathways linking these peripheral processes with altered
central nervous system (CNS) functioning and consequent delirium
are still poorly understood. Studies using animal models have
established that acute systemic inﬂammation, induced by peripheral
lipopolysaccharide (LPS) or E. Coli infection, induces deﬁcits in
hippocampal-dependent memory in rodent brains made vulnerable
by neurodegenerative disease [2] or age [3]. This disruption is transient
[2], and associated with greater induction of mRNA for pro-
inﬂammatory cytokines [2,3] and higher interleukin-1β (IL-1β)
cytokine levels in the hippocampus [4]. Furthermore, interleukin-1
receptor antagonist (IL-1ra) has been shown to block LPS-induced
working memory deﬁcits and systemically administered IL-1β is
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during dementia [5].
Recent studies have provided direct evidence of a relationship
between cytokine levels and delirium. Increased serum levels of
the pro-inﬂammatory cytokines interleukin-6 and -8 (IL-6, IL-8)
were found in elderly hip fracture patients with delirium [6,7].
Increased serum interferon gamma (IFN-γ), and decreases in the anti-
inﬂammatory insulin-like growth factor 1 (IGF-1) and IL-1ra have
been demonstrated in elderly medical patients with delirium [8,9]. In
cerebrospinal ﬂuid (CSF), signiﬁcantly higher levels of IL-8 have been
demonstrated in delirium after hip fracture [10]. Examination of CSF
in search of the pathogenesis of delirium has potential advantages due
to its proximity to the brain and its immune-privileged position behind
the blood brain barrier (BBB).
The mental status changes often referred to as ‘sickness behaviour
syndrome’ are thought to represent a coordinated set of behavioural
changes which, in health, promote survival [11]. Peripheral and central
production of cytokines leading to altered neurochemical signalling
may partly underpin this syndrome, with a potentially important role
for IL-1β [11]. There aremultiple routes bywhich systemic inﬂammato-
ry stimuli signal to the brain. Peripheral IL-1β can induce the synthesis
of prostaglandins, which cross the BBB [12], and IL-1β itself can enter
the CNS via an active transport with a saturable transport mechanism
[13,14], and via the circumventricular organs which lack a patent
BBB. IL-1β may also induce hyperpermeability of brain microvascular
endothelium, which forms the BBB [15]. Importantly, systemically
administered IL-1β has been shown in rodents to cross into the CNS,
so it cannot be assumed that CSF IL-1β has come from CNS synthesis
[14].
These well-conserved, protective, sickness behaviour mechanisms
may prove pathological if occurring over a long time period or in the
context of neurodegeneration [16]. Studies in an animal model of
neurodegeneration have shown that hippocampal microglial cells
(the brain's resident macrophages) are primed by primary pathology
to produce more IL-1β in response to peripheral inﬂammatory
challenge [17]. Similar immune cell changes in vulnerable brains may
underlie an exaggerated inﬂammatory response to peripheral injury,
seen in clinical practice when a seemingly minor inﬂammatory insult
induces a signiﬁcant deterioration in the elderly and those with demen-
tia, potentially including delirium and the hastening of cognitive and
functional decline [18,19].
This study aimed to investigateﬁve biomarkers known to be involved
in the neuroinﬂammatory process in rodents. We hypothesised that
delirium would be associated with increases in the pro-inﬂammatory
cytokines IL-1β and IFN-γ, and a marker of astrocytosis GFAP, and
decreases in anti-inﬂammatory IGF-1 and IL-1ra, and that this would
be shown in the CSF.
Methods
Participants
Patients over the age of 60 years awaiting surgery for hip fracture
were recruited in two university teaching centres: Royal Inﬁrmary of
Edinburgh (two studies) and Amsterdam Medical Centre during
November 2007 to January 2010 and October 2005 to February 2008
respectively. Patients were considered eligible unless they had recent
head injury, could not communicate ﬂuently in English or Dutch, or
were moribund on admission, were receiving steroid treatment or in
institutional care (second Edinburgh study), had surgery with general
anaesthetic planned, or inwhom informed consent could not be obtain-
ed. Informed written consent was sought from patients, or a proxy in
the case of patients lacking capacity to provide consent. Ethical approval
was obtained from the Scotland A Research Ethics Committee or
the Academic Medical Centre Ethics Committee in Amsterdam, the
Netherlands.Delirium assessments
Delirium assessments for each patient were carried out pre-
operatively on the day of surgery, followed by a post-operative assess-
ment 3–4 days later. Assessment consisted of mental status assessment
with cognitive tests, examination of case notes and discussion with
clinical staff, leading to a DSM-IV [20] diagnosis of delirium assessed
with the CAM [21]. Delirium cases were deﬁned as delirium present
pre-operatively and active at the time of sample collection (prevalent)
or delirium not present pre-operatively but developing post-
operatively (incident). Delirium was also broadly classed as being
present or absent at any stage during the peri-operative period.
Casenotes were searched for a pre-existing diagnosis of dementia, and
in the second Edinburgh study and Amsterdam study also, the Infor-
mant Questionnaire on Cognitive Decline in the Elderly [22] was used
to ascertain premorbid cognitive status, using an average score of 3.44
to indicate pre-existing dementia [23]. The Charlson co-morbidity
index was used to assess the burden of co-morbid disease [24].
Sample acquisition, processing and storage
Cerebrospinal ﬂuid (CSF)
Samples were taken before administration of spinal anaesthesia and
kept at 4 °C before being spun at 1000 g for 10min at 4 °C. Supernatants
were stored at−80 °C.
Blood
In a subgroup of participants in the Edinburgh study (N=24), 10ml
bloodwas collected. Sampleswere taken at the same time as the lumbar
puncture, kept at 4 °C and spunwithin three hours at 3000 g for 10min
at 4 °C. Aliquots of serum were stored at−80 °C before determination.
Assays
Concentrations of IL-1β, IL-1ra, IFN-γ and IGF-1 were measured
using normal sensitivity Quantikine ELISA kits from R&D systems
(Abingdon, UK), and GFAP concentration using an ELISA kit from
Biovendor (Modrice, Czech Republic). Samples, both serum and CSF,
were thawed directly before use and processed according to
manufacturer's instructions following the serum/plasma procedure.
Samples were assayed singly or in duplicate if sufﬁcient sample was
available. The IGF-1 assay involved a 100-fold dilution as a pre-
treatment step, and IL-1β samples were diluted 2-fold. The IL-1β bot-
tom standard was also diluted 2-fold in order to measure low concen-
tration in the samples. The manufacturer's recommended lower limits
of detection (LoD) were 1 pg/ml, 6.26 pg/ml, 8 pg/ml, 26 pg/ml and
45 pg/ml for IL-1β, IL-1ra, IFN-γ, IGF-1 and GFAP respectively.
Statistical analysis
Normality of distribution was assessed with histogram plots and
Kolgomorov–Smirnov test. Univariate analyses were performed using
Student's t-tests,Mann–Whitney U-tests and chi-square tests. Multivar-
iate analyses were performed using Kruskal–Wallis with pairwise post
hoc comparisons. Correlations were with Spearman's Rho. Due to the
low levels of detection of some cytokines, we conducted analyses
using values below the manufacturer's LoD where sufﬁcient cytokine
was detected to do statistical analyses. These values were extrapolated
from the standard curve. Due to the very low detectable levels of IL-
1β, to avoid any undue bias from these extrapolated values, we
performed two post hoc analyses. Firstly, we replaced all levels below
the LoDwith either a value of 0 (not detectable) or 1 (the limit of detec-
tion), and repeated the Mann–Whitney U test. Secondly, we created
a dichotomous variable “IL-1β detected”, assigning a value of 1 or 0
according to whether or not the cytokine was measured above the
manufacturer's LoD of 1 pg/ml, and comparing these rates of reliable
221E. Cape et al. / Journal of Psychosomatic Research 77 (2014) 219–225detection between groups with or without delirium, using chi-squared
tests. In order to adjust for potential confounders, a logistic regression
analysis model was built for CSF IL-1β, using delirium at any stage as
the dependent variable, using an Enter method. Co-variates were
chosen if theywere shown to bedifferent between groups in the univar-
iate analyses. The Statistical Package for the Social Sciences (SPSS)
version 19.0 was used for data analysis. A value of p b 0.05 was consid-
ered signiﬁcant.Results
Forty-three patients (32 females) were recruited from among a convenience sample
within the study period, N= 24 in Edinburgh and N= 19 in Amsterdam. In both centres,
this exploratory study was done in parallel with clinical work, with recruitment and
sampling being carried out when the investigator was able to arrange this. Therefore the
number of subjects was lower than expected because of logistical challenges. However,
all patients meeting eligibility criteria and with samples were included in the analysis.
Table 1 illustrates the baseline characteristics of the patient population. Mean age
was 81.5 ± 7.5 years; cases and controls did not differ (Table 1). Delirium was present
in 8/41 patients (20%) pre-operatively, 17/42 patients (40%) post-operatively and 19/43
patients (44%) at any stage. Nine of the 33 patients not delirious pre-operatively went
on to develop delirium post-operatively (27%). A history of dementia (N = 8) was
associated with a higher incidence of delirium (Table 1).CSF
Levels of cytokines in the CSF were generally low, with several below the
manufacturer's recommended LoD, and some were mostly undetected. Table 2 illustrates
the concentration of biomarkers detected in CSF. Delirium is classed according towhether
it was present pre-operatively (prevalent), only developed post-operatively (incident) or
never developed.CSF IL-1β
IL-1βwas detected in CSF at low concentrations: 20/44 (45%) of concentrations were
above the manufacturer's recommended LoD of 1 pg/ml. Post hoc analyses reassigning
results below the LoD of a value of either 0 or 1 did not alter the outcome of the results.
Chi-squared analysis of whether or not IL-1βwas detected in CSF revealed that if detected,
it wasmore likely to come from a patient in the delirium group (Pearson chi-squared 3.79
p = 0.05). Using all values including those extrapolated from the standard curve, CSF IL-
1β was higher in the group with delirium at any stage (median 1.02 pg/ml; IQR 0.66–
1.74) compared to the no delirium group (median 0.66 pg/ml; IQR 0–1.02) (Mann Whit-
ney U p = 0.02). Subgroup analysis revealed that CSF IL-1β was higher in patients with
incident delirium (median 1.74 pg/ml; IQR 1.02–1.74) compared to prevalent delirium
(0.84 pg/ml; 0.49–1.57) and those who never developed delirium (0.66 pg/ml; 0–1.02)
(Kruskal–Wallis p= 0.03) (Table 2, Supplementary Fig. 1). Post hoc pairwise comparisons
showed that this was due to the difference between incident delirium and never delirium
groups (p = 0.03).Table 1
Baseline characteristics of patient group
Delirium
N = 19
Age 81.3 years (SD 6.0)
Gender Female N = 14 (74%)
Hospital Edinburgh (study 1) N = 3
Edinburgh (study 2) N = 6
Amsterdam N = 10
Type of fracturea,b Femoral neck N = 9
Intertrochanteric N = 6
Periprosthetic N = 1
Type of surgery Hip replacement (bipolar or total) N = 10
Internal ﬁxation N = 9
Charlson co-morbidity index 5.00 (IQR 1.00–5.00)
Prior dementiac N = 7/17 (41.2%)
Number of regular medicationsa 5.50 (IQR 3.25–10.5)
Results expressed as median (interquartile range) or mean (standard deviation).
a Data not available for N = 12 Edinburgh study 1 participants.
b Data not available for N = 1 Amsterdam participant.
c Data not available for N = 2 participants.
d Student's t test.
e Pearson Chi-squared.
f Mann–Whitney U test.CSF IL-1ra
There was no difference in levels of CSF IL-1ra between those with (median
35.14 pg/ml; IQR 28.71–43.28) and without delirium at any stage (median 33.98 pg/ml;
IQR 26.95–44.43) (MannWhitney U p = 0.52). Subgroup analysis revealed that CSF IL-1ra
was higher in patients with prevalent delirium (median 70.75 pg/ml; IQR 65.63–73.01)
compared to those with incident delirium (31.06 pg/ml; 28.12–35.15) and those who
never developed delirium (33.98 pg/ml (IQR 28.71–43.28) (Kruskal–Wallis p = 0.04))
(Table 2, Supplementary Fig. 2). Post hoc pairwise comparisons showed that this was due
to the difference between incident and prevalent delirium groups (p = 0.04).
CSF GFAP, IFN-γ and IGF-1
No differences in GFAP levels were found in delirium at any stage (prevalent delirium
median 0.81 ng/ml (IQR 0.33–1.31) vs. incident delirium 0.61 ng/ml (0.46–0.76) vs. never
delirium 0.45 ng/ml (0.31–0.86), Kruskal–Wallis p = 0.58) (Table 2). IFN-γ and IGF-1
levels were all below the LoD in CSF and were not analysed further.
Serum
Serum samples were available from 24 patients. Table 3 illustrates the concentrations
of biomarkers detected in serum. Due to the smaller numbers in this exploratory substudy,
delirium was classed as either present at any time or absent. IL-1βwas found at concen-
trations above the LoD in 26% (6/23) of samples, and four of these samples were from
the delirious group (Pearson's chi-square 2.58 p = 0.11). No differences were seen in
serum levels of IL-1β, IL-1ra or IGF-1 with delirium at any stage (Table 3). IFN-γ and
GFAP were below the LoD in serum, and were not analysed further.
Correlation
Addressing the possibility that CSF IL-1β levelswere a function of elevated IL-1β in the
serum, we sought evidence for correlations between serum and CSF IL-1β, however there
wasno such correlation (Spearman's Rho0.11, p= 0.62). An alternative hypothesis is that
the combination of pre-existing dementia and subsequent hip fracture brought about CSF
IL-1β production. Six of the eight (75%) dementia patients were CSF IL-1β positive and the
other two had levels below 1 pg/ml but were detectable (0.32 and 0.66 pg/ml). Thirteen
of the 34 patients without prior dementia were positive (38%) (Pearson chi-squared p =
0.06). Moreover, for those patients where both serum and CSF analyses were possible, we
calculated CSF:serum ratios for IL-1β and found that this ratio was higher in the delirium
group (delirium group N = 7, median ratio 1 (IQR 0.18–1.27), no delirium group N = 7,
ratio 0 (0–0.48), MWU p = 0.02). There was no correlation between IL-1ra in CSF and
serum (Spearman's Rho 0.24, p = 0.27) and no differences in IL-1ra CSF:serum ratio in
groups with and without delirium (delirium group N = 8, median ratio 0.03 (IQR 0.02–
0.07), no delirium group N = 15, ratio 0.06 (0.04–0.09), MWU p = 0.11). Serum IL-1ra
and serum IL-1β levels were positively correlated (Spearman's Rho 0.50, p = 0.02). CSF
IL-1ra correlated negatively with both serum IGF-1 (Spearman's Rho−0.45, p = 0.03)
and with CSF GFAP (Spearman's Rho−0.48, p = 0.01).
Logistic regression analysis
The only demographic variable shown to be different between groups with and
without delirium at any stage was the presence of prior dementia (Table 1). A logistic
regression model was built to adjust for the effect of the presence of prior dementia on
the association between CSF IL-1β level and delirium status. TheWald statistic, odds ratiosNo delirium
N = 24
P value
81.3 years (SD 8.6) 0.99d
Female N = 18 (75%) 0.92e
Edinburgh (study 1) N = 9
Edinburgh (study 2) N = 6
Amsterdam N = 9
0.29e
Femoral neck N = 8
Intertrochanteric N = 5
Periprosthetic N = 1
0.99e
Hip replacement (bipolar or total) N = 10
Internal ﬁxation N = 14
0.47e
3.50 (IQR 0.25–6.00) 0.79f
N = 1/24 (4.2%) 0.00e
4.00 (IQR 1.00–6.00) 0.29f
Table 2
Concentrations of CSF markers in patients with delirium pre-operatively (prevalent), postoperatively (incident) and without delirium
CSF biomarker Prevalent delirium Incident delirium Never delirium P value
IL-1β (pg/ml) 0.84 (0.49–1.57) N = 8 1.74 (1.02–1.74) N = 9 0.66 (0.00–1.02) N = 24 0.03a
IL-1ra (pg/ml) 70.75 (65.63–73.01) N = 3 31.06 (28.12–35.15) N = 6 33.98 (28.71–43.28) N = 15 0.04a
GFAP (ng/ml) 0.81 (0.33–1.31) N = 8 0.61 (0.46–0.76) N = 9 0.45 (0.31–0.86) N = 24 0.58a
Results expressed as median (interquartile range).
a Kruskal–Wallis test.
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Table 4, along with pseudo-R2 values. CSF IL-1β remained signiﬁcant after adjusting for
prior dementia status (Table 4). There was no evidence of collinearity, and assumptions
for logistic regression were met.Discussion
These ﬁndings suggest an association of deliriumwith inﬂammation
in the CNS. In particular, they implicate the IL-1β family in this process.
IL-1β was increased in CSF in patients about to develop delirium,
indicating that CNS IL-1β production may be an early event in delirium
pathogenesis. IL-1ra levels were also increased in delirium, but only in
patients who already had delirium pre-operatively, indicating that its
production may be a later event in the delirium pathogenesis cascade.
A role for the IL-1β family in CNS inﬂammation underlying delirium
pathogenesis is plausible. IL-1β is increased in CSF in CNS inﬂammatory
disorders where there is manifest acute CNS damage, such as multiple
sclerosis (MS) [25–27]. To put the levels of CSF IL-1β in the present
study in a broader context, they were marginally higher than in
acute stroke (0.80 pg/ml) [28], and similar to those in dementia; in
Alzheimer's dementia levels range from 0.12 pg/ml [29] to 19.6 pg/ml
[30], in vascular dementia 0.3 pg/ml [31] and in Dementia with Lewy
Bodies 2.60 pg/ml [32]. Levels in age-matched controls range from
0.13 pg/ml to 23.3 pg/ml [30]. Levels in bacterial meningitis are several
hundred folds higher, e.g. 410.1 pg/ml [33], 974 pg/ml [34]. Many
studies reporting CSF IL-1β levels ﬁnd them to be close to or below
commercially-available assay LoD [30,32,35–37].
The source of CSF IL-1β could be peripheral, since IL-1β is capable of
crossing from the periphery into the CNS via different routes [12–14],
but given the lack of association between CSF and serum IL-1β levels
in the current study, this is unlikely. Plausible sources of central IL-1β
are macrophages of the choroid plexus and ventricular epithelium,
brain vascular endothelial cells or microglia, the brain's resident
macrophage population. All members of the IL-1 family (IL-1β, IL-1α
and IL-1ra), their receptors and regulatory molecules are present in
the brain, although expressed at very low levels in health [38]. It is
now well established, in rodents, that systemic inﬂammation such
as that caused by injury, surgery or infection, induces de novo CNS
expression of IL-1β transcripts [2,3,39] and synthesis of IL-1β protein
in circumventricular organs, the cerebro vasculature and in brain
parenchymal microglial cells [17,40]. IL-1β is also produced quickly
after various neurotoxic stimuli, predominantly by microglial cells, but
occasionally by neurones, astrocytes, oligodendrocytes and endothelialTable 3
Concentrations of serum markers in patients with delirium at any stage or without delirium
Serum biomarker Delirium at any stage
IL-1β (pg/ml) 0.66 (0.16–1.56) N = 9
IL-1ra (pg/ml) 1628.3 (SD 1086.7) N = 8
IGF-1 (ng/ml) 53.4 (SD 17.3) N = 9
Results expressed as median (interquartile range) or mean (standard deviation).
a Mann–Whitney U test.
b Student's t test.cells [41,42]. Intrathecal production of IL-1β has been demonstrated in
stroke patients [43]. That the central levels of IL-1β detected in this
study were higher than the peripheral levels, with no correlation
between the two, lends some weight to the suggestion that the source
of CSF IL-1β is central, although the relatively small numbers and
cross-sectional nature of the study make it difﬁcult to infer source and
causality. Furthermore, the increased CSF:serum IL-1β ratios in delirium
versus no delirium offer tentative support for the microglial priming
hypothesis that systemic inﬂammation produces exaggerated CNS
inﬂammatory responses in those with prior CNS pathology and that
this may have a role in delirium [2].
Interleukin-1β has pleiotropic actions in the CNS [44], and is strongly
implicated in sickness behaviour [11,45,46]. Delirium has recently been
suggested as a maladaptive form of this evolutionarily conserved, co-
ordinated system of behaviour in vulnerable individuals [47]. Animal
studies modelling delirium or acute cognitive dysfunction induced by
systemic inﬂammation in aged rodents or thosewith prior neurodegen-
eration have consistently shown exaggerated CNS IL-1β responses
to equivalent systemic stimulation [2–4,48]. Moreover, it has
recently been shown that IL-1β is causative and synergises with cyclo-
oxygenase 1-mediated prostaglandins to induce acuteworkingmemory
deﬁcits in an animal model relevant to delirium during dementia [5].
Physiological levels of IL-1βmay be required for memory formation,
with both deﬁciency and excess leading to decrements in hippocampal-
dependent memory function in animal studies [42]. IL-1β is also
thought to initiate a cascade of events leading to neuroinﬂammation,
and in rodent models it exacerbates injury from other insults such as
trauma or ischaemia [44]. IL-1β also has an effect on activation of the
hypothalamic–pituitary–adrenal axis at all levels, leading to an increase
in CNS cortisol levels [12,49]. Elevated CSF cortisol has recently
been demonstrated in delirium [50]. Increased microglial expression
of IL-1β has been reported in Alzheimer's disease [51]; this chronic
expression is thought to contribute to plaque formation and precedes
neurodegeneration [52]. IL-1β was found to be elevated in 75% of
those with dementia in the current study, although importantly all of
the patients had also suffered hip fracture, which would be predicted
to drive IL-1β expression in the brain [39], particularly in those with
prior CNS pathology [17]. The ﬁnding of elevated IL-1β in the CNS in
delirium has biologically plausible implications in terms of the role of IL-
1β in sickness behaviour, memory and neuroinﬂammation, and potential
consequences in terms of neurotoxicity if this response is sustained.
We found elevated CSF IL-1β in thosewith incident delirium, that is,
thosewhowere about to develop delirium, often in the immediate post-No delirium P value
0.00 (0.00–0.66) N = 14 0.08a
MWU = 35.0
760.0 (SD 505.3) N = 15 0.06b
t = −2.14
68.3 (SD 36.9) N = 14 0.27b
t = 1.13
Table 4
Logistic regression model for CSF IL-1β
Co-variate CSF IL-1βmodel
Wald ORa 95% CIb of ORa P value
Prior dementia 5.64 0.06 (0.01–0.62) 0.02
CSF IL-1b 5.32 3.31 (1.20–9.15) 0.02
Constant 0.39 2.10 0.53
This table shows the results of the multivariate logistic regression analysis for CSF IL-1β,
built to adjust for the potential confounding effect of prior dementia on delirium status.
The dependent variable was delirium at any stage.
Pseudo-R2 0 (Cox and Snell), 0.31 (Nagelkerke) 0.42.
a OR: Odds ratio.
b CI: Conﬁdence interval.
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of CNS IL-1β is an early phenomenon in deliriumpathogenesis. Alterna-
tively, post-operative delirium may have a different pathogenesis
to pre-operative delirium, perhaps due to the more homogeneous
insult of surgery and anaesthesia compared with potentially different
precipitants in those who had perhaps fallen and fractured because
they were already delirious, or developed delirium in association with
pain, immobility, analgesia, fasting or dehydration in the pre-operative
period.
The anti-inﬂammatory IL-1ra acts to inhibit IL-1β signalling through
competitive binding [53]. It has been reported that IL-1ra production is
delayed by 30 min compared to that of IL-1 β in response to ischaemia
[54]. In this study, IL-1ra was higher only in patients with active
deliriumsuggesting that thiswas after a rise in IL-1β, however in clinical
terms, a 30 minute delay is unlikely to be relevant. It may be speculated
that this production of IL-1ra is a neuroprotective response to the
increased production of IL-1β; for example after traumatic brain injury,
patients who mount a greater CSF IL-1ra response have a better neuro-
logical outcome [55], and IL-1ra is currently being trialled as a therapy in
subarachnoid haemorrhage and severe traumatic brain injury [56,57]. It
will be interesting to see if a rise in IL-1ra during a delirium episode
correlates with a quicker or more complete recovery.
IL-1ra concentrations are required to be 50–100-fold higher than
those of IL-1β to inhibit binding, as IL-1ra has a very short half-life of
4–6 h [58], and because very small concentrations of IL-1β are sufﬁcient
to activate its receptor [59]. In this study, IL-1ra concentrations were
approximately 50-fold higher than IL-1β (Tables 2 and 3).
This study did not replicate previous ﬁndings of Adamis et al. of a
decrease in serum IGF-1 [8]. In that study plasma measurements were
taken at up to 4 time points during admission, while here the relatively
small sample size and single blood collection may not have detected
a decrease in IGF-1. CSF IGF-1 was not detected with the ELISA kit
used, indicating that it is present at concentrations below the LoD
of 26 pg/ml. Other authors have demonstrated levels of CSF IGF-1 in
elderly control subjects of 4.30–4.40 pg/ml [60,61], and in elderly
cohorts with Alzheimer's disease of 9.44 pg/ml [61], so it is possible
that the ELISA we used was not sufﬁciently sensitive to detect IGF-1 in
this setting.
IFN-γ was found to be below the LoD of 8 pg/ml in CSF and serum
from all participants. Levels of CSF IFN-γ reported in the literature for
healthy controls are 2.49 pg/ml [62] and 3.98 pg/ml [63]. IFN-γ was
not detected in a cohort of patients with probable Alzheimer's disease,
other dementias and cognitively normal elderly patients, with a LoD of
2 pg/ml [64]. CSF IFN-γ has been reported at levels of 53.53 pg/ml in
herpes simplex encephalitis [35], 13.85 pg/ml in bacterial meningitis
[63], and 4.26 pg/ml in MS patients within one week of acute relapse
[63]. It is therefore likely that IFN-γ is present in low levels in CSF
following hip fracture and in delirium. It is also possible that we did
not detect a rise in IFN-γ in our cohort with hip fracture, since it is a
sterile injury, as opposed to general medical cohorts in whom a rise
in serum has been demonstrated previously, where the incidence of
infection precipitating delirium may be higher [8].Astrocytes, which express the IL-1β receptor, are involved in neuro-
inﬂammation, when they multiply and produce inﬂammatory interme-
diates [65]. Van Munster et al. have found increased GFAP staining in
hippocampal sections from patients who died with delirium [66], but
here we found no signiﬁcant difference in CSF levels. CSF levels of
GFAP were negatively correlated with CSF IL-1ra; if the presence of
increased IL-1ra is a neuroprotective response, greater IL-1ra produc-
tion may lead to less astrocyte activation. The levels we detected in
our elderly cohort were similar to those found in younger patients
with MS [67] and older patients with movement disorders [68], and
lower than that seen in traumatic brain injury [69], and stroke [70].
GFAP is a structural protein of the cytoskeleton of ﬁbrillary astrocytes,
and its release into CSF is usually associated with acute CNS injury or
astrogliosis [68,71].
Some limitations of the study should be addressed. Fifty-ﬁve per
cent of IL-1β values were below the LoD of the assay. Although we
tried to ensure that the use of extrapolated values did not substantially
bias the ﬁndings, this may have been the case. One would also suspect a
contribution of dementia to these ﬁndings, since premorbid dementia
was strongly associated with the development of delirium peri-
operatively and cytokine levels can be different in dementia. Important-
ly, the results of the logistic regression analysis suggest that CSF IL-1β
remains associated with delirium after adjusting for the presence of
prior dementia. In future studies the possibility of undiagnosed neuro-
degenerative disease should be addressed as robustly as possible with
the use of informant history to assess premorbid cognition. An impor-
tant strength of the methodology is the use of a planned urgent spinal
anaesthetic to gain valuable CSF in a frail group with high rates of
delirium, along with robust assessments for pre- and post-operative
delirium. Since delirium ﬂuctuates, it is always possible that we missed
some mild or late cases, but we tried to minimise this by including
casenote review and discussion with nursing staff.
In conclusion, this study supports the hypothesis that there are
inﬂammatory mechanisms in delirium, and for the ﬁrst time suggests
a role for CNS IL-1β in the deliriumpathogenesis cascade. A future larger
study should conﬁrm the increase in CSF IL-1β and IL-1ra. Analysis of
longitudinal deliriumdata andmultiple timepoints of sample collection
will allow a thorough exploration of these and other cytokines putative-
ly involved in delirium pathogenesis.
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